Data from several U.S. cities, including from syphilis outbreak
investigations and the Gonococcal Isolate Surveillance Project (GISP),
suggest that an increasing number of men who have sex with men (MSM)
are acquiring STDs.1-5 Increases in STDs among MSM are consistent
with data suggesting that an increasing number of MSM are participating
in sexual behaviors that place them at risk for STDs and HIV infection.6Several
factors may be contributing to this change, including the availability
of highly active antiretroviral therapy (HAART).7Because
STDs and the behaviors associated with them increase the likelihood
of acquiring and transmitting HIV infection,8the rise
in STDs among MSM may be associated with an increase in HIV incidence
among MSM.9
Observations
National notifiable STD surveillance data reported to CDC do not
include information regarding sexual behaviors; therefore, national
trends in STDs among MSM in the United States are not available.
Data from enhanced surveillance projects are presented in this section
to provide information regarding STDs in MSM.
Monitoring Trends in Prevalence of STDs, Tuberculosis,
and HIV Risk Behaviors among Men Who Have Sex with Men
(MSM Prevalence Monitoring Project)
From 1999 through 2003, nine U.S. cities participating in the MSM Prevalence
Monitoring Project submitted syphilis, gonorrhea, chlamydia, and HIV test
data to CDC from 67,588 MSM visits to STD clinics. Overall, 57,570 MSM visits
were submitted from six public STD clinics (Denver, Long Beach, New York
City, Philadelphia, San Francisco, and Seattle) and 10,018 MSM visits were
submitted from three STD clinics in community-based, gay men's health
clinics (Chicago, the District of Columbia, and Houston). In 2003, the nine
participating sites submitted information from 18,783 MSM visits to STD clinics.
In addition, in 2003, Fenway Community Health (Boston), a community-based,
gay men's primary care clinic also participating in the MSM Prevalence
Monitoring Project, submitted syphilis, gonorrhea, and chlamydia test data
to CDC from 22,673 primary care visits by men. The MSM Prevalence Monitoring
Project includes data from culture and non-culture tests collected during
routine care and reflects testing practices at participating clinics. City-specific
medians and ranges were calculated for the proportion of tests done and STD
and HIV test positivity among MSM visits.
Syphilis, STD Clinics, 1999-2003
In 1999, 69% (range: 49-93%) of MSM visiting participating
STD clinics had a nontreponemal serologic test for syphilis
(STS) performed compared with 79% (range: 37-89%) in 2003.
Overall, median syphilis seroreactivity among MSM increased
from 4.1% (range:3.7-13.1%) in 1999 to 10.5% (range:4.7-16.6%)
in 2003 (FigureDD).
Gonorrhea, STD Clinics, 1999-2003
Median gonorrhea positivity in MSM was 13.7% (range: 12.9-16.5%)
in 1999 and 15.3% (range: 13.7-17.2%) in 2003 (Figure
EE).
In 2003, 76% (range: 46-90%) of MSM were tested for urethral
gonorrhea, 34% (range: 2-59%) were tested for rectal gonorrhea,
and 46% (range: 3-83%) were tested for pharyngeal gonorrhea.
In 2003, median urethral gonorrhea positivity in MSM was
13.3% (range: 6.2-17.7%), median rectal gonorrhea positivity
was 6.0% (range: 2.8-8.3%), and median pharyngeal gonorrhea
positivity was 2.8% (range: 0.4-9.2%).
In 2003, urethral gonorrhea positivity was 11.5% (range:
6.3-17.2%) in whites, 18.8% (range:10.5-30.3%) in African-Americans,
and 12.4% (range: 5.3-21.9%) in Hispanics. Rectal gonorrhea
positivity was 6.1% (range:
3.0-14.3%) in whites, 5.6% (range: 2.9-10.1%) in African-Americans,
and 4.3% (range: 2.5-6.7%) in Hispanics. Pharyngeal gonorrhea
positivity was 4.3% (range:0.2-9.4%) in whites, 5.3% (range:
1.4-10.7%) in
African-Americans, and 5.9% (range:
1.3-8.7%) in Hispanics (Figure FF).
In 2003, gonorrhea positivity was higher in HIV-positive
MSM compared with MSM who were HIV-negative or of unknown HIV
status. Urethral gonorrhea positivity was 17.8% (range: 10.3-25.8%)
in HIV-positive MSM and 12.1% (range 5.4-16.9%) in MSM who
were HIV-negative or of unknown HIV status; rectal gonorrhea
positivity was 11.0% (range: 4.4-12.2%) in HIV-positive MSM
and 6.1% (range: 2.5-11.1%) in MSM who were HIV-negative or
of unknown HIV status; pharyngeal gonorrhea positivity was
5.8% (range: 3.2-9.2%) in HIV-positive MSM and 2.7% (range:
0.4-9.1%) in MSM who were HIV-negative or of unknown HIV status
(Figure GG).
HIV Infection, STD Clinics, 2003
In 2003, a median of 52% (range: 44-60%) of MSM visiting
participating STD clinics and not previously known to be HIV-positive
were tested for HIV; median HIV positivity was 3.9% (range:
2.1-6.4%). HIV positivity varied by race and ethnicity, but
tended to be highest in African-American MSM. HIV positivity
was 3.5% (range: 1.7-4.1%) in whites, 8.6% (range 3.6-9.5%)
in African-Americans, and 4.4% (range: 1.7-14.3%) in Hispanics
(Figure FF).
In 2003, median HIV prevalence among MSM, including persons
previously known to be HIV-positive and persons testing HIV-positive
at their current visit, was 11.0% (range 2.8-19.0%). HIV prevalence
was 9.0% (range: 2.5-14.0%) in whites, 18.5% (range: 2.7-25.5%)
in African-Americans, and 9.5% (range: 2.3-35.7%) in Hispanics.
Chlamydia, STD Clinics, 2003
In 2003, a median of 81% (range: 47-93%) of MSM visiting participating
STD clinics were tested for urethral chlamydia; median urethral chlamydia
positivity was 8.9% (range: 3.9-10.5%) (Figure
FF). Median positivity
was 7.9% (range: 3.8-17.0%) in HIV-positive MSM and 6.7% (range: 3.9-10.0%)
in MSM who were HIV-negative or of unknown HIV status (Figure
GG).
STD Testing and Positivity, Community-based, Gay Men's
Primary Care Clinic, 2003
Among men with a nontreponemal serologic test for syphilis, 5.8% had
a reactive syphilis test result; 34.7% of men with reactive syphilis
serologies were identified as new syphilis cases. Among men tested for
gonorrhea, urethral positivity was 14.6%, rectal positivity was 10.1%,
and pharyngeal positivity was 1.9%. Among men tested for urethral chlamydia,
positivity was 5.4%.
Nationally Reported Syphilis Surveillance Data
Primary and secondary (P&S) syphilis increased in the United States during
2002-2003. Between 2002 and 2003, there was a 13% increase in the number
of P&S syphilis cases among men and a 24% decrease in the number of cases
among women (Tables 27 and 28). Trends in the syphilis male-to-female rate
ratio, which are assumed to reflect syphilis trends among MSM, have been
increasing in the United States during recent years (Figure
31). In 2003,
the rate of reported P&S syphilis among men (4.2 cases per 100,000 males)
was 5.2 times greater than the rate among women (0.8 cases per 100,000 females).
The overall male-to-female syphilis rate ratio has risen steadily since 1996
when it was 1.2 (Figure 31). The increase in the male-to-female rate ratio
occurred among all racial and ethnic groups between 2002 and 2003. Additional
information on syphilis can be found in the Syphilis
section.
Gonococcal Isolate Surveillance Project (GISP)
The Gonococcal
Isolate Surveillance Project (GISP),
a collaborative project among selected STD clinics,
was established in 1986 to monitor trends in antimicrobial
susceptibilities of strains of Neisseria gonorrhoeae in the United States.
GISP also reports the percentage of Neisseria
gonorrhoeae isolates obtained from MSM.10Overall,
the proportion of isolates coming from MSM in GISP
clinics increased from 4% in 1988 to 19.6% in 2003,
with most of the increase occurring after 1993 (Figure
HH). Additional information on GISP may be found
in the
Gonorrhea section.
The proportion of isolates coming from MSM varies
geographically with the largest percentage on the
west coast (Figure II).
Due to increases in the proportion of isolates from
MSM that are fluoroquinolone-resistant (Figure
22),
in 2004 CDC recommended that fluoroquinolones no longer
be used to treat gonorrhea among MSM.11
1 Centers for Disease Control and Prevention.
Resurgent bacterial sexually transmitted disease among men
who have sex with men – King County, Washington, 1997-1999.
MMWR 1999;48:773-7.
2 Centers for Disease Control and Prevention.
Outbreak of syphilis among men who have sex with men –Southern
California, 2000. MMWR 2001;50:117-20.
3 Centers for Disease Control and Prevention.
Gonorrhea among men who have sex with men – selected
sexually transmitted disease clinics, 1993-1996. MMWR 1997;46:889-92.
4 Fox KK, del Rio C, Holmes K, et. al. Gonorrhea
in the HIV era: A reversal in trends among men who have sex
with men. Am J Public Health 2001;91:959-964.
5 Centers for Disease Control and Prevention.
Primary and secondary syphilis among men who have sex with
men – New York City, 2001. MMWR 2002;51:853-6.
6 Stall R, Hays R, Waldo C, Ekstrand M, McFarland
W. The gay ‘90s: a review of research in the 1990s on
sexual behavior and HIV risk among men who have sex with men.
AIDS 2000;14:S1-S14.
7 Scheer S, Chu PL, Klausner JD, Katz MH,
Schwarcz SK. Effect of highly active antiretroviral therapy
on diagnoses of sexually transmitted diseases in people with
AIDS. Lancet 2001;357:432-5.
8 Fleming DT, Wasserheit JN. From epidemiologic
synergy to public health policy and practice: the contribution
of other sexually transmitted diseases to sexual transmission
of HIV infection. Sex Transm Infect 1999;75:3-17.
9 Centers for Disease Control and Prevention.
HIV/AIDS Surveillance Report 2002;14.
10 Centers for Disease Control and Prevention.
Sexually Transmitted Disease Surveillance 2003 Supplement:
Gonococcal Isolate Surveillance Project (GISP) Annual Report
2003. Atlanta, GA: U.S. Department of Health and Human Services
(in press).
11 Centers for Disease Control and Prevention.
Increases in fluoroquinolone-resistant Neisseria gonorrhoeae among men who have sex with men – United States, 2003,
and revised recommendations for gonorrhea treatment, 2004.
MMWR 2004;53:335-338.